Overview

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Acarbose
Exenatide
Glimepiride
Insulin
Insulin Glargine
Linagliptin
Liraglutide
Metformin
Pioglitazone
Sitagliptin Phosphate